Novartis AG (NVS) annual results, year to 31 December 2018: revenue USD 44,833 million, from the 20-F
Novartis AG files a 20-F with the SEC once a year, in US dollars. In the year to 31 December 2018 it reported revenue from the sale of goods of USD 44,833 million, up 5.8% on the year before. Its profit attributable to shareholders was USD 12,611 million, up 63.7%, and diluted earnings per share USD 5.38.
The year to 31 December 2018, against the year before
| Year to | Dec 2017 † | Dec 2018 † |
|---|---|---|
| Revenue from the sale of goods | 42,381 | 44,833 |
| Cost of sales | 13,633 | 14,510 |
| Gross profit | 29,771 | 31,589 |
| Research and development | 8,389 | 8,489 |
| Selling, general and administrative | 12,465 | 13,717 |
| Operating profit | 8,702 | 8,403 |
| Profit before tax | 9,102 | 14,095 |
| Income tax | 1,603 | 1,295 |
| Profit for the year | 7,703 | 12,614 |
| Profit attributable to shareholders | 7,703 | 12,611 |
| Filing | 20-F | 20-F |
USD million, from the 20-F on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed. A line the company does not file under the standard tag is left out rather than estimated.
USD per ordinary share, as filed.
Cash flow
| Year to | Dec 2017 † | Dec 2018 † |
|---|---|---|
| Cash from operations | 12,621 | 14,272 |
| Purchase of property, plant and equipment | 1,325 | 1,254 |
| Free cash flow | 11,296 | 13,018 |
| Dividends paid | 6,495 | 6,966 |
| Filing | 20-F | 20-F |
USD million. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.
Balance sheet at year end
| Year to | Dec 2017 † | Dec 2018 † |
|---|---|---|
| Total assets | 133,079 | 145,563 |
| Equity attributable to shareholders | 74,168 | 78,614 |
| Cash and cash equivalents | 8,860 | 13,271 |
| Borrowings, as filed | 23,583 | 25,660 |
| Inventories | 6,867 | 6,956 |
| Goodwill | 31,750 | 35,294 |
| Filing | 20-F | 20-F |
USD million, at each fiscal year end.
Ratios on the filed lines
| Year to | Dec 2017 † | Dec 2018 † |
|---|---|---|
| Return on year-end equity | 10.4% | 16.0% |
| Effective tax rate | 17.6% | 9.2% |
| Filing | 20-F | 20-F |
Arithmetic on the filed lines of the same year.
Every annual report here
- Year to 31 December 2025
- Year to 31 December 2024
- Year to 31 December 2023
- Year to 31 December 2022
- Year to 31 December 2021
- Year to 31 December 2020
- Year to 31 December 2019
- Year to 31 December 2018, this page
- Year to 31 December 2017
- Year to 31 December 2016
Source
20-F for the year to 31 December 2018, filed 26 January 2021, accession 0001370368-21-000006: the filing on EDGAR. All of Novartis AG's filings: EDGAR company page. The figures are in US dollars as filed.
The same record on your computer
GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.